Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05673148 |
TitleERASur研究：测试在有限转移性结直肠癌的常规系统疗法基础上增加全烧蚀疗法的效果 | 阶段
第三阶段
|
Date Added 2023-01-06 |
地点
Arizona, United States
California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Maryland, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Dakota, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
化疗 |
标签
MSS/ MMRp
|
| NCT ID NCT05672316 |
TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | 阶段
第 1 阶段
|
Date Added 2023-01-05 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, Regorafenib |
标签
MSS/ MMRp
|
| NCT ID NCT05653882 |
TitleA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-12-16 |
地点
California, United States
Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05652894 |
TitleA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | 阶段
第三阶段
|
Date Added 2022-12-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
HX008, Investigator's Choice Chemotherapy |
标签
MSI-H/ MMRd
|
| NCT ID NCT05627635 |
TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-11-25 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT05611034 |
TitleIn Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | 阶段
第 1 阶段
|
Date Added 2022-11-09 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
oxaliplatin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05608044 |
TitleA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases | 阶段
第二阶段
|
Date Added 2022-11-08 |
地点
Arizona, United States
California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States 比利时 巴西 法国 格鲁吉亚 意大利 Russian Federation 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, Regorafenib, TAS-102 |
标签
MSS/ MMRp
|
| NCT ID NCT05609370 |
TitleA Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-11-08 |
地点
Alaska, United States
Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States 澳大利亚 中国 波多黎各 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, capecitabine, LBL-007, Tislelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT05493683 |
TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-08-09 |
地点
China,China,China,China,China,China
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Disitamab vedotin, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05491083 |
TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | 阶段
第 1 阶段
|
Date Added 2022-08-08 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
尚未招聘
|
药物
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
标签
MSI-H/ MMRd, MSS/ MMRp
|
